Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control

American Journal of Hypertension

Volumn 16, Issue 5 I, 2003, Pages 381-386

  Holzgreve, Heinrich ^a,d   Nakov, Roumen ^b   Beck, Katrin ^b   Janka, Hans Uwe ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Knoll AG   (Germany)

^c Zentralkrankenhaus Bremen Nord   (Germany)

^d Kardiologische Praxis   (Germany)

Author keywords

Antihypertensvie agents; Glucose intolerance; Hemoglobin A1c; Hypertension; Type 2 diabetes

Indexed keywords

ATENOLOL; CHLOROTHIAZIDE; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; TRANDOLAPRIL; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0037727837     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00062-1     Document Type: Article

References (18)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
2. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, Faire Ud, Mörlin C, Karlberg BE, Wester PO, Björck J-E, for the Captopril Prevention Project (CAPPP) study group: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.
3. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester P-O, Hedner T, de Faire U, for the STOP-Hypertension-2 study group: Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients With Hypertension-2 study. Lancet 1999;354:1751-1756.
4. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
5. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL, for the Atherosclerosis Risk in Communities Study: Hypertension and antihypertensvie therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-912.
6. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981;II:539-543.
7. Suter PM, Vetter W: Metabolic effects of antihypertensive drugs. J Hypertens 1995;13(Suppl 4):S11-S17.
8. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M: ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992;6:175-179.
9. Petrie JC, O'Brien ET, Littler WA, de Swiet M: Recommendations on blood pressure measurement. Br Med J 1986;293:611-615.
10. Cifková R, Nakov R, Novozámská E, Hejl Z, Petrzilková Z, Poledne R, Stávek P, Compagnone D: Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 2000;14:347-354.
11. Middeke M, Richter WO, Schwandt P, Holzgreve H: The effects of antihypertensvie combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus atenolol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther 1997;35:231-234.
12. Fernández R, Puig JG, Rodriguez-Pérez JC, Carrido J, Redon J, on behalf of the TRAVEND Study Group: Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001;15:849-856.
13. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720.
14. Khaw K-T, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322:15-18.
15. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parring H-H: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44:1303-1309.
16. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-828.
17. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.
18. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.